4//SEC Filing
Nosenzo John 4
Accession 0000899243-22-013963
CIK 0001665988other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 9:14 PM ET
Size
9.4 KB
Accession
0000899243-22-013963
Insider Transaction Report
Form 4
Nosenzo John
Chief Commercial Officer
Transactions
- Exercise/Conversion
Class A Common Stock
2022-04-01+106,485→ 149,895 total - Exercise/Conversion
Restricted Stock Units
2022-04-01−106,485→ 0 total→ Class A Common Stock (106,485 underlying) - Sale
Class A Common Stock
2022-04-04$11.12/sh−65,963$733,502→ 83,932 total
Footnotes (5)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
- [F2]Includes 40 shares acquired under the Company's 2021 Employee Stock Purchase Program on April 1, 2022.
- [F3]Reflects shares sold to cover taxes upon the vesting of RSUs on April 1, 2022 pursuant to a standing 10b5-1 instruction.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.48, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]The RSUs vested on April 1, 2022.
Documents
Issuer
Bioventus Inc.
CIK 0001665988
Entity typeother
Related Parties
1- filerCIK 0001835973
Filing Metadata
- Form type
- 4
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 9:14 PM ET
- Size
- 9.4 KB